Perrigo Company (NYSE:PRGO) VP Todd W. Kingma sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, December 28th. The stock was sold at an average price of $88.52, for a total transaction of $132,780.00. Following the sale, the vice president now directly owns 19,565 shares of the company’s stock, valued at approximately $1,731,893.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Perrigo Company (PRGO) opened at $87.16 on Tuesday. Perrigo Company has a one year low of $63.68 and a one year high of $91.73. The stock has a market capitalization of $12,280.00, a price-to-earnings ratio of -9.52, a P/E/G ratio of 1.86 and a beta of 0.64. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.24 and a current ratio of 1.72.

Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Thursday, November 9th. The company reported $1.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.28. Perrigo had a positive return on equity of 11.60% and a negative net margin of 26.28%. The firm had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the business posted $1.65 earnings per share. The firm’s revenue for the quarter was down 2.0% on a year-over-year basis. analysts predict that Perrigo Company will post 4.88 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 19th. Investors of record on Friday, December 1st were paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.73%. The ex-dividend date of this dividend was Thursday, November 30th. Perrigo’s dividend payout ratio (DPR) is presently -6.99%.

A number of research firms have recently weighed in on PRGO. Canaccord Genuity set a $100.00 price target on shares of Perrigo and gave the stock a “buy” rating in a research report on Monday. Cantor Fitzgerald set a $107.00 price target on shares of Perrigo and gave the stock a “buy” rating in a research report on Thursday, December 28th. Argus raised shares of Perrigo from a “hold” rating to a “buy” rating and set a $93.00 price target for the company in a research report on Friday, December 8th. Barclays raised their price target on shares of Perrigo to $93.00 and gave the stock an “overweight” rating in a research report on Monday, December 4th. Finally, Jefferies Group reissued a “hold” rating and set a $81.00 price target on shares of Perrigo in a research report on Friday, November 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $92.13.

Institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp lifted its stake in Perrigo by 1.7% during the second quarter. State Street Corp now owns 6,757,086 shares of the company’s stock worth $510,294,000 after purchasing an additional 112,287 shares during the last quarter. Sei Investments Co. lifted its stake in Perrigo by 7.5% during the third quarter. Sei Investments Co. now owns 131,284 shares of the company’s stock worth $11,114,000 after purchasing an additional 9,192 shares during the last quarter. Cetera Advisors LLC bought a new position in Perrigo during the third quarter worth $398,000. Andra AP fonden lifted its stake in Perrigo by 9.9% in the third quarter. Andra AP fonden now owns 16,700 shares of the company’s stock valued at $1,414,000 after buying an additional 1,500 shares during the last quarter. Finally, Howard Hughes Medical Institute bought a new stake in Perrigo in the second quarter valued at $778,000. Hedge funds and other institutional investors own 83.29% of the company’s stock.

WARNING: “Perrigo Company (PRGO) VP Todd W. Kingma Sells 1,500 Shares” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/02/perrigo-company-prgo-vp-todd-w-kingma-sells-1500-shares.html.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Insider Buying and Selling by Quarter for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.